3. Eriksen JL, Wszolek Z, Petrucelli L (2005) Molecular pathogenesis of Parkinson disease. Arch Neurol 62: 353–357. 4. Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophys- iology of Parkinson’s disease. Annu Rev Neurosci 28: 57–87. 5. Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75: 333–366. 6. Sung JY, Kim J, Paik SR, Park JH, Ahn YS, et al. (2001) Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein. J Biol Chem 276: 27441–27448. 7. Liu J, Zhou Y, Wang Y, Fong H, Murray TM, et al. (2007) Identification of proteins involved in microglial endocytosis of alpha-synuclein. J Proteome Res 6: 3614–3627. 8. Lee HJ, Patel S, Lee SJ (2005) Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 25: 6016–6024. 9. Sung JY, Park SM, Lee CH, Um JW, Lee HJ, et al. (2005) Proteolytic cleavage of extracellular secreted a-synuclein via matrix metalloproteinases. J Biol Chem 280: 25216–25224. 10. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, et al. (2000) Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson’s disease and normal subjects. Neurosci Lett 287: 65–67. 11. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, et al. (2003) Alpha-synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma. FASEB J 17: 1945–1947. 12. Kim S, Seo JH, Suh YH (2004) Alpha-synuclein, Parkinson’s disease, and Alzheimer’s disease. Parkinsonism Relat Disord 10: S9–13. 13. Richter-Landsberg C, Gorath M, Trojanowski JQ, Lee VM (2000) alpha- synuclein is developmentally expressed in cultured rat brain oligodendrocytes. J Neurosci Res 62: 9–14. 14. Mori F, Tanji K, Yoshimoto M, Takahashi H, Wakabayashi K (2002) Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment. Exp Neurol 176: 98–104. 15. Perez RG, Hastings TG (2004) Could a loss of alpha-synuclein function put dopaminergic neurons at risk? J Neurochem 89: 1318–1324. 16. Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT, Jr. (1996) NACP, a protein implicated in Alzheimer’s disease and learning, is natively unfolded. Biochemistry 35: 13709–13715. 17. Dedmon MM, Lindorff-Larsen K, Christodoulou J, Vendruscolo M, Dobson CM (2005) Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J Am Chem Soc 127: 476–477. 18. Bertoncini CW, Jung YS, Fernandez CO, Hoyer W, Griesinger C, et al. (2005) Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc Natl Acad Sci USA 102: 1430–1435. 19. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276: 2045–2047. 20. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet 18: 106–108. 21. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164–173. 22. Gasser T (2005) Genetics of Parkinson’s disease. Curr Opin Neurol 18: 363–369. 23. Bertoncini CW, Fernandez CO, Griesinger C, Jovin TM, Zweckstetter M (2005) Familial mutants of alpha-synuclein with increased neurotoxicity have a destabilized conformation. J Biol Chem 280: 30649–30652. 24. Cookson MR (2009) alpha-Synuclein and neuronal cell death. Mol Neurode- gener 4: 9. 25. Kim YS, Joh TH (2006) Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson’s disease. Exp Mol Med 38: 333–347. 26. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38: 1285–1291. 27. Forno LS (1996) Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol 55: 259–272. 28. Banati RB, Daniel SE, Blunt SB (1998) Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson’s disease. Mov Disord 13: 221–227. 29. Knott C, Stern G, Wilkin GP (2000) Inflammatory regulators in Parkinson’s disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 16: 724–739. 30. Mirza B, Hadberg H, Thomsen P, Moos T (2000) The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson’s disease. Neuroscience 95: 425–432. 31. Vila M, Jackson-Lewis V, Guegan C, Wu DC, Teismann P, et al. (2001) The role of glial cells in Parkinson’s disease. Curr Opin Neurol 14: 483–489. 32. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, et al. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22: 1763–1771. 33. Delgado M, Ganea D (2003) Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson’s disease by blocking microglial activation. FASEB J 17: 944–946. a-Syn and Innate Immunity 34. Sanchez-Pernaute R, Ferree A, Cooper O, Yu M, Brownell AL, et al. (2004) Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson’s disease. J Neuroinflammation 1: 6. 35. Zhang W, Wang T, Pei Z, Miller DS, Wu X, et al. (2005) Aggregated alpha- synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J 19: 533–542. 36. Theodore S, Cao S, McLean PJ, Standaert DG (2008) Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 67: 1149–1158. 37. Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, et al. (2008) Synuclein activates microglia in a model of Parkinson’s disease. Neurobiol Aging 29: 1690–1701. 38. Chung CY, Koprich JB, Siddiqi H, Isacson O (2009) Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroin- flammation precede dopaminergic neuronal loss in a rat model of AAV alpha- synucleinopathy. J Neurosci 29: 3365–3373. 39. Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M (2010) Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson’s disease. PLoS One 5: e8784. 40. Gu XL, Long CX, Sun L, Xie C, Lin X, et al. (2010) Astrocytic expression of Parkinson’s disease-related A53T alpha-synuclein causes neurodegeneration in mice. Mol Brain 3: 12. 41. Roodveldt C, Christodoulou J, Dobson CM (2008) Immunological features of alpha-synuclein in Parkinson’s disease. J Cell Mol Med 12: 1820–1829. 42. Lee SJ (2008) Origins and effects of extracellular alpha-synuclein: implications in Parkinson’s disease. J Mol Neurosci 34: 17–22. 43. Benner EJ, Banerjee R, Reynolds AD, Sherman S, Pisarev VM, et al. (2008) Nitrated alpha-Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons. PLoS One 3: e1376. 44. Zhang W, Dallas S, Zhang D, Guo JP, Pang H, et al. (2007) Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia 55: 1178–1188. 45. Thomas MP, Chartrand K, Reynolds A, Vitvitsky V, Banerjee R, et al. (2007) Ion channel blockade attenuates aggregated alpha-synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson’s disease. J Neurochem 100: 503–519. 46. Reynolds AD, Glanzer JG, Kadiu I, Ricardo-Dukelow M, Chaudhuri A, et al. (2008) Nitrated alpha-synuclein-activated microglial profiling for Parkinson’s disease. J Neurochem 104: 1504–1525. 47. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, et al. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290: 985–989. 48. Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H (2000) Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 275: 18344–18349. 49. Joo SH, Kwon KJ, Kim JW, Hasan MR, Lee HJ, et al. (2010) Regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by alpha- synuclein in rat primary glial cells. Neurosci Lett 469: 352–356. 50. Lee EJ, Woo MS, Moon PG, Baek MC, Choi IY, et al. (2010) Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol 185: 615–623. 51. Park JY, Paik SR, Jou I, Park SM (2008) Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson’s disease. Glia 56: 1215–1223. 52. Klegeris A, Pelech S, Giasson BI, Maguire J, Zhang H, et al. (2008) Alpha- synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol Aging 29: 739–752. 53. Klegeris A, Giasson BI, Zhang H, Maguire J, Pelech S, et al. (2006) Alpha- synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J 20: 2000–2008. 54. Su X, Federoff HJ, Maguire-Zeiss KA (2009) Mutant alpha-Synuclein overexpression mediates early proinflammatory activity. Neurotox Res 16: 238–254. 55. Jensen PH, Hojrup P, Hager H, Nielsen MS, Jacobsen L, et al. (1997) Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha- synuclein/NAC precursor that bind Abeta and NAC. Biochem J 323: 539–546. 56. Cole NB, Murphy DD, Grider T, Rueter S, Brasaemle D, et al. (2002) Lipid droplet binding and oligomerization properties of the Parkinson’s disease protein alpha-synuclein. J Biol Chem 277: 6344–6352. 57. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT, Jr. (2002) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418: 291. 58. Moussa CE, Wersinger C, Rusnak M, Tomita Y, Sidhu A (2004) Abnormal migration of human wild-type alpha-synuclein upon gel electrophoresis. Neurosci Lett 371: 239–243. 59. Schagger H, von Jagow G (1991) Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. Anal Biochem 199: 223–231. PLoS ONE | www.plosone.org 12 October 2010 | Volume 5 | Issue 10 | e13481